3 Australian Growth Stocks With Revenue Growth Up To 17%

Australia’s central bank has just lifted interest rates to an 18 year high, which puts extra pressure on high debt, low growth businesses. Companies that can still grow quickly in this setting, and where founders and executives own meaningful stakes, can look especially interesting because management feels the same pain and reward as shareholders. This piece highlights three fast growing Australian stocks with heavy insider backing from this focused screener.

The three stocks highlighted here offer a compelling starting point if you want exposure to fast growing businesses where management is heavily invested alongside you. However, if you want the names that matter most, these 26 high growth high conviction stocks are the strongest companies we've found.

Regis Healthcare (ASX:REG)

Regis Healthcare runs aged care homes, home care services and retirement living in Australia, with growth tied closely to expanding higher acuity residential and in home care. It generates about A$1.35b from this integrated care segment and has a market value of roughly A$1.49b.

Regis Healthcare fits this fast growth, high insider ownership theme because its core aged care operations link rising demand for more intensive support with management pushing hard on scalable residential and in home services.

While the new 2% RAD retention framework and higher advertised room prices support a growing capital like earnings stream, any change in government policy settings around RADs or retention rates would directly affect this contribution to EBITDA and long term earnings.

Everything hinges on how one pressure point in the broader funding mix shapes future pricing power and earnings quality.

That pressure point is only the starting line, and the full narrative for Regis Healthcare shows how Regis Healthcare’s growth ambitions and policy risk could be pulling in opposite directions.

Liontown (ASX:LTR)

Liontown focuses on lithium, gold and nickel exploration, with the Kathleen Valley lithium project anchoring its appeal to the fast growing, insider backed theme. The business generated about A$639 million from mineral exploration and development in Australia and has a market value near A$2.0b.

Liontown sits in the sweet spot for this screener, with a lithium development story that is already shaping into a real operating business and still backed by growth focused leadership.

The company has initiated trials with higher contamination ore, achieving higher lithium recovery rates while maintaining strong recovery even with lower-grade material, which could improve net margins by optimizing processing costs over time.

What happens to Liontown’s earnings profile if one key production lever shifts from incremental efficiency gain to a step change in cost relief?

If that shift in cost profile is what you are watching, the full narrative for Liontown outlines how Liontown’s risk, funding and growth ambitions could be decoupling.

Telix Pharmaceuticals (ASX:TLX)

Telix Pharmaceuticals focuses on precision radiopharmaceuticals for cancer imaging and treatment. This lines up cleanly with a screener looking for fast growing businesses where management is closely tied to high conviction, revenue-facing drug programs rather than early stage research alone.

Telix Pharmaceuticals generates about $704.7 million from Precision Medicine and $277.1 million from Manufacturing Solutions, giving it a diversified commercial base, and the group carries a market value near A$4.4b.

Telix Pharmaceuticals provides a commercial radiopharma platform where growth expectations depend heavily on how effectively its lead prostate and brain cancer programs convert scientific promise into durable revenue.

"Their primary revenue generating imaging agents: 'Illuccix' and 'Gozellix', are utilised in 23+ countries worldwide, including key markets such as the U.S, Europe, China and Japan, with revenue figures of $803.8m (USD) in the 2025 Financial Year."

The real swing factor is how evolving competitive and regulatory pressure around its cancer imaging portfolio ultimately filters through to pricing power and margins.

That pricing question is exactly what the full narrative for Telix Pharmaceuticals unpacks, tracing how Telix Pharmaceuticals could turn regulatory pressure into accelerating market share and stronger economics for its pipeline.

Seeking Fresh Alternatives Before They Fly?

Fresh opportunities move fast. Breakout stories gain momentum, laggards keep dropping, and the best ideas get caught by early investors before the crowd. Scan what is still under the radar for now and act while conditions remain favorable.

• Spot strong balance sheets before momentum chasers arrive by reviewing the curated list of solid balance sheet and fundamentals (12 results) that keeps financial strength front and center while it still matters.
• Follow structural demand for clean baseload energy by tracking hand picked utilities and builders inside the 16 nuclear energy infrastructure stocks while they are still flying under most radars.
• Review potential inflation hedges and currency weak spots by assessing miners grouped in the focused 34 elite gold producer stocks before shifts in metal prices change entry points.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com